Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 31, 2011 (May 25, 2011)

 

 

Endo Pharmaceuticals Holdings Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-15989    13-4022871

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

100 Endo Boulevard, Chadds Ford, PA    19317
(Address of principal executive offices)    (Zip Code)

Registrant’s telephone number, including area code (610) 558-9800

Not Applicable

Former name or former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) On May 25, 2011, Endo Pharmaceuticals Holdings Inc. held their Annual Meeting of Shareholders.

(b) Shareholders voted on the matters set forth below.

 

1. The nine nominees for election to the Board of Directors of the Company (representing all of the members of the Board of Directors of the Company) were elected, each for a one-year term to serve until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified:

 

Nominee    Votes For      Abstentions     

Broker

Non Votes

 

John J. Delucca

     100,635,944         1,863,187         4,876,025   

David P. Holveck

     101,842,921         656,210         4,876,025   

Nancy J. Hutson, Ph.D.

     100,639,855         1,859,276         4,876,025   

Michael Hyatt

     101,396,084         1,103,047         4,876,025   

Roger H. Kimmel

     101,414,416         1,084,715         4,876,025   

William P. Montague

     101,916,405         582,726         4,876,025   

David B. Nash, M.D., M.B.A.

     101,893,486         605,645         4,876,025   

Joseph C. Scodari

     100,595,113         1,904,018         4,876,025   

William F. Spengler

     100,642,024         1,857,107         4,876,025   

 

2. The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011was approved based upon the following votes:

 

Votes for approval

     104,962,799   

Votes against

     2,232,843   

Abstentions

     179,514   

Broker non-votes

     0   

 

3. The proposal to approve, on an advisory basis, named executive officer compensation was approved based upon the following votes:

 

Votes for approval

     91,630,932   

Votes against

     5,177,098   

Abstentions

     5,691,101   

Broker non-votes

     4,876,025   

 

4. The proposal on the frequency of future advisory votes on executive compensation received the following votes:

 

For one year

     78,601,035   

For two years

     309,714   

For three years

     17,922,808   

Abstentions

     5,665,574   

Broker non-votes

     4,876,025   

See Item 5.07(d) below.

 

5. The proposal to approve the Company’s Employee Stock Purchase Plan was approved based upon the following votes:

 

Votes for approval

     94,874,637   

Votes against

     1,906,294   

Abstentions

     5,718,200   

Broker non-votes

     4,876,025   


6. Other such matters as may properly come before the Annual Meeting or any adjournment or postponement thereof

None.

(c) Not applicable.

(d) Based upon the results set forth in item (b) (4) above, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)
By:  

/S/ CAROLINE B. MANOGUE

Name:   Caroline B. Manogue
Title:   Executive Vice President, Chief Legal Officer & Secretary

Dated: May 31, 2011